Aspirin protects against Barrett's esophagus

July 23, 2012

Aspirin use appears to reduce the risk of Barrett's esophagus (BE), the largest known risk factor for esophageal cancer, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

"The protective effect of aspirin use appears robust because the analyses suggests a dose-response relationship in which high-dose aspirin was significantly associated with decreased Barrett's esophagus risk," said Chin Hur, MD, MPH, of the Massachusetts General Hospital Institute for Technology Assessment and lead author of this study. "It would not be advisable at this time for patients to start taking aspirin, particularly at higher doses, if preventing Barrett's esophagus is the only goal. However, if additional data confirms our findings and an individual at high risk for development of Barrett's esophagus and esophageal cancer also could derive additional benefits, most notably cardiovascular, aspirin could be a consideration."

Dr. Hur and his team of researchers analyzed characteristics of 434 BE patients for factors that might be used in screening and management. In addition to finding that those taking aspirin were 44 percent less likely to have BE, they also found that men were more than three times more likely to develop BE than women.

The incidence of esophageal cancer has been increasing at an alarming rate during the past few decades; current attempts at targeted screening for this type of cancer focus on identifying BE. Nonsteroidal anti-inflammatory drugs (), particularly aspirin, have been associated with reduced esophageal . Although there have been many studies analyzing NSAID and aspirin for esophageal cancer or BE progression to this cancer, few have explored NSAIDs for BE prevention.

More information: Read AGA's medical position statement on the management of BE.

Related Stories

Even low-dose aspirin may increase risk of GI bleeding

September 12, 2011

The risk of gastrointestinal (GI) bleeding needs to be considered when determining the potential preventive benefits associated with low-dose aspirin for cardiovascular disease and cancer. According to a new study in Clinical ...

Recommended for you

New treatment options for a fatal leukemia

July 27, 2015

In industrialized countries like in Europe, acute lymphoblastic leukemia is the most common form of cancer in children. An international research consortium lead by pediatric oncologists from the Universities of Zurich and ...

Modified DNA building blocks are cancer's Achilles heel

July 22, 2015

In studying how cells recycle the building blocks of DNA, Ludwig Cancer Research scientists have discovered a potential therapeutic strategy for cancer. They found that normal cells have highly selective mechanisms to ensure ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.